Concordia Healthcare (
TSX: CXR,
Stock Forum) significantly increased its footprint when the company announced today that it had entered into a definitive asset purchase agreement with privately held Covis Pharma S.a.r.l and Covis Injectables S.a.r.l for a total of US$1.2 billion.
According to the
news release, the transaction will add 18 branded and authorized products to the company’s portfolio with the transaction expected to be over 50% accretive to adjusted EPS in 2015.
Key products include, Nilandron®, treatment of metastatic prostate cancer; Dibenzyline®, treatment of pheochromocytoma; Lanoxin®, treatment of mild-to-moderate heart failure and atrial fibrillation; and, Plaquenil®, treatment of lupus and rheumatoid arthritis.
The company plans to facilitate the transaction through a mix of term loans, bonds and equity and has entered into a commitment letter with Royal Bank of Canada (“RBC”) whereby RBC has agreed to provide credit facilities and bridge commitments of up to US$1.6 billion to fully pay for the acquisition price and refinance all outstanding Concordia debt.
The acquisition is expected to close in Q2 2015 and is still subject to customary conditions including the receipt of regulatory approvals. The Board of Directors of all related parties have approved the acquisition.
Company CEO, Mark Thompson commented, Covis' strong commercial momentum will have an immediate and material impact on our top and bottom line financial results. In the longer-term, this transaction creates greater scale and diversification for Concordia, which should support the continued execution of our aggressive growth plans.”
Concordia Healthcare was in the news recently when
the Toronto-based company provided a corporate update in the middle of February.
Shares climbed 27.85% on the news to $82.03 per share.
Currently there are 28.9m outstanding shares with a market cap of $2.4 billion.